New Detailed Data From Phase 3 Study Show Amgen's Repathaâ¢ (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol